-
AVXL Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Anavex Life Sciences (AVXL)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 132.19 mm | 132.19 mm | 132.19 mm | 132.19 mm | 132.19 mm | 132.19 mm |
Cash burn (monthly) | 2.19 mm | 1.57 mm | 4.78 mm | 4.41 mm | 2.22 mm | 2.57 mm |
Cash used (since last report) | 9.35 mm | 6.70 mm | 20.41 mm | 18.82 mm | 9.48 mm | 10.96 mm |
Cash remaining | 122.84 mm | 125.48 mm | 111.78 mm | 113.37 mm | 122.71 mm | 121.22 mm |
Runway (months of cash) | 56.1 | 79.9 | 23.4 | 25.7 | 55.3 | 47.2 |
13F holders | Current |
---|---|
Total holders | 146 |
Opened positions | 23 |
Closed positions | 23 |
Increased positions | 47 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 153.64 bn |
Total shares | 27.88 mm |
Total puts | 788.20 k |
Total calls | 515.30 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 6.74 mm | $38.29 bn |
Vanguard | 4.74 mm | $26.92 bn |
STT State Street | 3.07 mm | $17.41 bn |
Geode Capital Management | 1.88 mm | $10.70 bn |
Nwam | 910.48 k | $5.17 bn |
Wealthgarden F.S. | 910.48 k | $5.17 bn |
Two Sigma Investments | 830.62 k | $4.72 bn |
MS Morgan Stanley | 718.56 k | $4.08 bn |
NTRS Northern Trust | 695.96 k | $3.95 bn |
Charles Schwab Investment Management | 665.98 k | $3.78 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jan 25 | Sandra Boenisch | Stock Option Common Stock | Grant | Acquire A | No | No | 8.57 | 12,500 | 107.13 k | 12,500 |
15 Jan 25 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 8.57 | 125,000 | 1.07 mm | 125,000 |
15 Jan 25 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 7.54 | 166,666 | 1.26 mm | 166,000 |
19 Dec 24 | Sandra Boenisch | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 12,500 | 67.00 k | 12,500 |
19 Dec 24 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 5.36 | 125,000 | 670.00 k | 125,000 |
19 Nov 24 | Christopher U Missling | Stock Option Common Stock | Grant | Acquire A | No | No | 10.09 | 125,000 | 1.26 mm | 250,000 |